Google Alert - "Myeloproliferative neoplasms" OR "polycythemia vera" OR myelofibrosis OR "essential thrombocythemia" · Scour

Eli Lilly Expands Blood Cancer Capabilities with Ajax Acquisition

Lilly to acquire Ajax Therapeutics

Eli Lilly announces acquisition of Ajax Therapeutics for up to $2.3 billion

Lilly buying Ajax for up to $2.3B for next-gen JAK assets

Eli Lilly to buy Ajax Therapeutics for up to $2.3 billion in blood cancer bet

Eli Lilly (LLY) Stock: Pharmaceutical Giant Acquires Ajax Therapeutics in $2.3B Blood Cancer Deal

Pharmaceutical Executive Daily: FDA Approves Caplyta for Adults with Schizophrenia

Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and ...

Eli Lilly to buy Ajax Therapeutics for up to $2.3 billion in blood cancer bet

Lilly bets $2.3B on Ajax's JAK approach

Lilly snags Cambridge biotech for up to $2.3B in latest acquisition

Lilly's $2.3bn acquisition of Ajax targets breakthroughs in blood cancer treatments

Lilly pens $2.3B deal for next-gen JAK inhibitor biotech Ajax

Lilly to Acquire Ajax Therapeutics in Up to $2.3 Billion Oncology Deal

Eli Lilly is acquiring blood cancer drug developer Ajax Therapeutics for up to $2.3 billion

Lilly Drops $2.3 Billion On Cambridge Cancer Upstart In Myelofibrosis Power Play

Lilly acquiring Ajax Therapeutics in deal worth up to $2.3B

Lilly to buy startup Ajax in bid for a better JAK drug

Eli Lilly Enters $ 2.3 Billion Agreement to Acquire Ajax Therapeutics

Lilly lands third oncology deal in 3 weeks, inking up to $2.3B for Ajax

Log in to enable infinite scrolling